Compare Medpace Holdings Inc (MEDP) vs Oklo Inc (OKLO) Price & Performance

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

OKLO trades at $45.13, up 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but posted a wider net loss of $0.28 per share, missing estimates. Key milestones include the Groves reactor achieving criticality, though cash burn remains high with operating cash flow negative $117 million in 2026.

The outlook balances significant growth potential in nuclear energy against substantial execution risks. Analyst sentiment is strongly bullish (77% buy ratings), but investors face risks from persistent losses, high spending, and project delays. The stock's trajectory hinges on successful commercialization of its Aurora reactors by the targeted 2028 startup.